Form 4: Kiniksa CAO Megna Reports Routine Share Transactions

Kiniksa Pharmaceuticals' Chief Accounting Officer, Michael R. Megna, reported the acquisition of 175 Class A Ordinary Shares from RSU vesting and the disposition of 85 shares for tax purposes.

Summary

• Michael R. Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals International, plc, reported transactions involving Class A Ordinary Shares.
• On October 4, 2025, 175 Class A Ordinary Shares were acquired through the vesting of Restricted Share Units (RSUs).
• Concurrently, 85 Class A Ordinary Shares were disposed of at a price of $38.49 per share to cover tax withholding obligations.
• Following these transactions, Michael R. Megna beneficially owns 38,101 Class A Ordinary Shares directly.
• The RSUs vest over a four-year period, with 25% vesting on each anniversary of the grant date, October 4, 2021.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing reports routine, pre-scheduled insider transactions related to RSU vesting and tax withholding, which do not indicate any new positive or negative developments for the company.

Positives

• The acquisition of shares through RSU vesting indicates continued equity ownership and alignment of interests between management and shareholders.
• RSU vesting is a standard component of executive compensation, reflecting ongoing employment and performance.

Negatives

• The disposition of 85 shares, while for tax purposes, results in a slight reduction in direct beneficial ownership.

Future Outlook

NA

Industry Context

This filing represents a routine insider transaction common across publicly traded companies, where executive compensation often includes equity awards like Restricted Share Units (RSUs) that vest over time. The subsequent disposition of shares for tax withholding is a standard practice upon vesting.

Stakeholder Impact

• Shareholders: Minimal impact, as these are routine, non-discretionary transactions by an officer.
• Employees: Reflects standard equity compensation practices for executives.

Key Dates

Recommendation

The filing details routine insider transactions related to RSU vesting and subsequent tax withholding, which do not provide new material information to alter an investment thesis. These are standard compensation events and do not reflect a discretionary buy or sell decision based on new company performance or outlook.

Keywords

Kiniksa Pharmaceuticals, KNSA, Form 4, Insider Transaction, Restricted Share Units, RSU Vesting, Share Disposition, Michael Megna, Chief Accounting Officer